This is the world’s most comprehensive hematology event of the year and it is very important to prepare the meeting as CML patient advocates in order not to miss out on any key session about chronic myeloid leukemia.
Below you can find some key information about CML sessions hoping it will assist you to prepare and outline your days and make the most out of your time whilst at #ASH19.
We are especially proud this year because of the strong presence of the patient advocacy evidence-based with two important posters of the leukemia patient advocacy community:
- The CML Advocates Network Paper “Chronic Myeloid Leukemia Patients’ Views on Psychological Support Throughout the Treatment-Free Remission Journey”
- The Acute Leukemia Advocates Network Paper ”Identifying Differences in the Quality of Life of Patients with Acute Leukemia: A Global Survey”
FRIDAY, DECEMBER 6, 2019
iCMLf Forum for Physicians from Emerging Economic Regions
“Overcoming Challenges in the Management of CML”
If you would like to attend the iCMLf Forum for Physicians from Emerging Regions to be held on December 6, 2019, from 12-2 pm at the Rosen Plaza Hotel in Orlando (USA), please reserve your place by sending an email to email@example.com
This year’s focus is on:
- Perspectives on the future of CML (Professor Jorge Cortés)
- Modeling response when testing less frequently than monthly (A/Professor Susan Branford)
- Re-evaluating TKI use in pregnancy, with perspectives from Dr. Chelysheva from Russia and Dr. Boquimani from Brazil.
This annual Forum is presented in partnership with our member The Max Foundation.
SATURDAY, DECEMBER 7, 2019
– ASH CML Education Programme –
The Education Programme, chaired by Hemant Malhotra, MD, FRCP, Mahatma Gandhi Medical College Hospital, deals with these three topics:
- The US Experience with Generic Imatinib in CML: Did Cost Predictions Meet Reality?. Gary H. Lyman, MD.
- Meeting the Needs of CML Patients in Resource-Poor Countries: a Roundtable Discussion. Pat Garcia-Gonzalez; Hemant Malhotra, MD, FRCP and Jerald P. Radich, MD.
Moderator: Franck E Nicolini, MD,PhD Moderator: Sudipto Mukherjee, MD, PhD
– SPECIAL-INTEREST SESSION –
Chair: Bob Löwenberg, MD, PhD, Editor-in-Chief, Blood, Erasmus University Medical Center.
The ability to communicate one’s work effectively by publication in high-impact journals is a benchmark for success in academic medicine. Even high-quality work may not be accepted if not presented in a well-crafted manuscript. This talk will provide insight into the elements of a high-quality manuscript worthy of publication in Blood and tips on avoiding common errors that might result rejection.
– 631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Basic and Translational Studies to Improve Treatment Outcomes and Identify Immune Mediators of Treatment-free Remission. –Saturday, December 7, 2019: 12:00 PM-1:30 PM Tangerine 2 (WF2), Level 2 (Orange County Convention Center)
Moderators: Daniela S. Krause, MD, University of Frankfurt and Rob Welner, Ph.D., UAB
SUNDAY, DECEMBER 8, 2019
Moderators: Carlo Gambacorti-Passerini, MD, University of Milano Bicocca and Pia Raanani, MD, Davidoff Cancer Center, Beilinson Hospital
CML Advocates Network Poster “2934. Chronic Myeloid Leukemia Patients’ Views on Psychological Support Throughout the Treatment-Free Remission Journey”
MONDAY, DECEMBER 9, 2019
Moderators: Elisabetta Abruzzese, MD, Hematology Unit, S. Eugenio Hospital, Tor Vergata University and B. Douglas Smith, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
– SPECIAL-INTEREST SESSION –
Annually, reviewers from the U.S. Food and Drug Administration (FDA) and leadership from the Oncology Center of Excellence and the Office of Hematology and Oncology host a session intended to foster dialogue between reviewers of benign and malignant hematology drug products and patients affected by the drug approval process. The session will be interactive and allow time for discussion between the FDA reviewers and the patients.
– SPOTLIGHT SESSION –
Childhood Chronic myeloid leukemia (CML) is a rare disease. Recent data indicates biological differences between adults and children. Evidence-based guidelines have been established for adult CML, but it is challenging to develop similar recommendations in pediatrics because of the rarity of the disease. Recent approval of second-generation tyrosine kinase inhibitors (TKI) in addition to imatinib has provided more treatment options for pediatric patients, but limited data on efficacy and safety often makes management difficult. Further, host factors are different in actively growing children and children develop distinct morbidities of TKI, such as delayed growth.
Dr. Etan Orgel will explore the emerging data for MPAL biology and clinical outcomes as they relate to therapy selection and future research directions. Dr. Nobuko Hijiya will discuss the recent advances in the biology of childhood CML, challenges to the management of children, and the feasibility of a pediatric TKI “Stopping” study.
- To check all CML Sessions, click HERE.
- To check all CML Poster sessions, click HERE.
- To check all CML Oral sessions, click HERE.
- To check other interesting sessions for CML patient advocates, click HERE.
If you are coming to #ASH19, don’t miss any of them, they will all be really interesting!